A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Haloperidol (HALOPERIDOL)

Typical Antipsychotic class · 21 generic manufacturers · 81 ANDAs filed at FDA.

First FDA approval1986-01-14
Generic availableYes · 21 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$39.4M in CY2024 Part D spend1.4M claims · 240K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.123/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.134
Across all dosage forms in distribution.
Highest NADAC
$0.151
Range is tight.
Plans with PA
544 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Haloperidol used for?

Haloperidol is a Typical Antipsychotic medication tracked in Medicare Part D.

Is there a generic for Haloperidol?

Yes. 81 ANDAs filed at FDA, 21 generic manufacturers currently shipping.

How much does my plan pay for Haloperidol?

Across 329 Part D plans, Haloperidol averages $0.134/unit (NADAC). Lowest available: $0.123/unit. Highest in distribution: $0.151/unit.

Is Haloperidol on the FDA shortage list?

Haloperidol has been discontinued by its manufacturer(s).

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Typical Antipsychotic2 alternatives in D1
01
Pimozide
Typical Antipsychotic
$1.25Lowest NADAC
1Generic mfrs
$2.1MCY24 Part D spend
Compare →
02
Thiothixene
Typical Antipsychotic
$0.659Lowest NADAC
3Generic mfrs
$3.3MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.